



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

2

Complete if Known

Application Number	10/045,400
Filing Date	November 8, 2004
First Named Inventor	Chul-so MOON
Art Unit	1642
Examiner Name	Misook YU
Attorney Docket Number	006586.00003

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
my		US- 6,255,293	07-03-2001	KIMCHI	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
my		BORROW et al., "The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9", <u>Nat Genet</u> , February 1996, Vol. 12, No. 2, pp. 159-167, Abstract.	
		BRABENDER et al., "Hypermethylation of Multiple Genes in Non-Small Cell Lung Cancer", <u>Proceedings of the American Association for Cancer Research: Molecular Biology</u> 18, Abstract #2566, March 2001, Vol. 42, p. 76	
		CALVO et al., "Altered HOX and WNT7A expression in human lung cancer", <u>PNAS</u> , November 7, 2000, Vol. 97, No. 23, pp. 12776-12781.	
		CELETTI et al., "Characteristic patterns of HOX gene expression in different types of human leukemia", <u>Int J Cancer</u> , January 21, 1993, Vol. 53, No. 2, pp 237-244, Abstract.	
		ESTELLER et al., "Detection of Aberrant Promoter Hypermethylation of Tumor Suppressor Genes in Serum DNA from Non-Small Cell Lung Cancer Patients", <u>Cancer Research</u> , 01 Jan. 1999, Vol. 59, pp 67-70, esp. the abstract, page 67 second column, page 68.	
		FIELD, et al., "Microsatellite instability in non-small-cell lung cancer and bronchial lavage specimens", <u>Proceedings of the American Association for Cancer Research: Molecular Biology/Biochemistry</u> 5, Abstract #1015, March 1997, Vol. 38, p. 151.	X
		KIM et al., "Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer", <u>Oncogene</u> , 2001, Vol. 20, pp 1765-1770.	
		KIMCHI et al., "DAP-kinase: a pro-apoptotic gene with tumor suppressor activity", <u>Oncology Research</u> , 2001, Vol. 12, p. 262.	
		KISSIL et al., "DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene", <u>Oncogene</u> , July 24, 1997, Vol. 15, No. 4, pp. 403-407, Abstract.	
		MAO et al., "Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis", <u>Science</u> , February 2, 1996, Vol. 271, pp. 659-662.	

Examiner
Signature

Misook YU

Date
Considered

1-12-08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/08b(08-03)), no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/045,400
Filing Date	November 8, 2004
First Named Inventor	Chul-so MOON
Art Unit	1642
Examiner Name	Misook YU
Attorney Docket Number	006586.00003

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
my		MOON et al., "Expression of Human HOXA9 Gene as a Potential Novel Tumor Marker", <u>Proceedings of the American Association for Cancer Research: Molecular Biology 1</u> , Abstract #330, March 2001, Vol. 42, p. 62.	
I		TANG et al., "Hypermethylation of the DAP-kinase CpG Island Correlates with Aggressive Biological Behavior in Stage 1 non-small Cell Lung Cancer, <u>Proceedings of the American Association for Cancer Research Annual Meeting: Molecular Biology 6</u> , Abstract #497, March 2000, Vol. 41, page 78, the entire document.	X
		TANG et al., "Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell-lung cancer", <u>Journal of the National Cancer Institute (Bethesda)</u> , 20 Sept. 2000, (Vol. 92, No. 18, pp 1511-1516, esp. the last paragraph of page 1511, first column of page 1512, the paragraph bridging page 1512 to 1513, Fig. 1, the paragraph bridging page 1514 to 1515, the first column at page 1515.	
		THORSTEINSDOTTIR et al., "Overexpression of HOXA10 in Murine Hematopoietic Cells Perturbs both Myeloid and Lymphoid Differentiation and Leads to Acute Myeloid Leukemia", <u>Molecular and Cellular Biology</u> , Jan. 1997, Vol. 17, No. 1, pp. 495-505.	
		TIBERIO et al., "HOX gene expression in human small-cell lung cancers xenografted into nude mice", <u>Int J Cancer</u> , August 15, 1994, Vol. 58, No. 4, pp. 608-615, Abstract.	

Examiner
Signature

misook yu

Date
Considered

1-12-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.